

MEDICAL REPORT

Clinical Trials More than 450 clinical trials, including national trials, are currently underway at Cooper University Health Care, addressing a wide range of the latest pharmacologic, surgical, and device-related therapeutic options. Cooper's robust research program offers clinicians and their patients access to some of the most novel therapies and innovative trials in the region.




The following list represe	ents some of the clinical trials curre	ISSUE 16 – 2019			
Study Area	Principal Investigator (PI)	Contact Info	Study Type	Study Description	Main Inclusion Criteria
Anesthesia	Kelly A. Bolkus, DO	Brian M. 856.968.7333	Treatment	Evaluate Regional vs. General Anesthesia for Hip Fracture Surgery.	 Age ≥50 years. Eligible to receive either spinal block or GA.
Anesthesia	Kingsuk Ganguly, MD	Brian M. 856.968.7333	Drug Study	Single blind evaluation of Exparel vs bupivacaine in Robotic Thoracic Surgery.	 Age ≥18 years. Having robotic wedge resection or lobectomy. Weight 155 lbs. and above.
Hematology/ Oncology Breast	Kamel Abou Hussein, MD	Lisa A. 856.325.6719	Drug Study	This study evaluates the efficacy and safety of Pembrolizumab as adjuvant therapy for triple receptor-negative breast cancer.	 Women or men age ≥18 years. ER-, PR- and HER2-negative breast cancer. Residual disease of 1cm or greater and/or positive lymph nodes after neoadjuvant chemotherapy.
Hematology/ Oncology Surgical Oncology Lung	David D. Shersher, MD	Lorraine G. 856.735.6231	Screening Study	This is a early detection study for lung cancer.	 Men and Women Age ≥ 50 years for current smokers or former smokers who quit less than 15 years ago with a smoking history of 20 pack years or more and a lung cancer risk factor. Men and Women Age ≥ 55 years current smokers or former smokers who quit less than 15 years ago with a smoking history of 30 pack years.
Obstetrics and Gynecology	Meena Khandelwal, MD	Elena S. 856.968.7547	Prospective Evaluation	This study aims to assess the prevalence of sleep disorder breathing in pregnant women with a singleton gestation who develop hypertensive disorder of pregnancy (HDP) compared to women without HDP.	 Age ≥18 years. Diagnosis of a hypertensive disorder of pregnancy. Greater than 20 weeks pregnant. One fetus.



Study Area	Principal Investigator (PI)	Contact Info	Study Type	Study Description	Main Inclusion Criteria
Trauma Abdominal Sepsis Associated - AKI	Ju-Lin Wang, MD	Janika S.R. 856.361.1324	Drug Study	This study evaluates treatment and outcomes for patients with surgery for abdominal sepsis associated - AKI.	 Males or females 18 years of age to 80 years of age. Diagnosis of abdominal sepsis requiring surgical or IR control. AKI either on admission or within 48 hours from diagnosis of abdominal sepsis.
Trauma Necrotizing Infections	Ju-Lin Wang, MD	Janika S.R. 856.361.1324	Drug Study	This study evaluates treatment and outcomes for patients with surgery for necrotizing soft tissue infections.	 Males or females age ≥18 years. Clinical diagnosis of necrotizing soft tissue infection and requires surgery for treatment.
Urology	Allen D. Seftel, MD	Trisha N. 856.968.7269	Drug Study	To compare the effect of testosterone replacement therapy (TRT) and matching placebo on major adverse cardiovascular events (MACE).	1. 45-80 years old with hypogonadism and cardiovascular disease.
Vascular Surgery AAA	Joseph V. Lombardi, MD	Jonelle O. 856.342.2150	Device Study	This study evaluates the safety and efficacy of a polymer and endovascular graft combination in the treatment of abdominal aortic aneurysms (AAA).	 Age >18 years. Must have an aneurysm/ulcer of the abdominal aorta.
Vascular Surgery AAA	Joseph V. Lombardi, MD	Jonelle O. 856.342.2150	Device Study	This study evaluates a thoracic branch device in the treatment of aneurysms of the aortic arch and descending thoracic aorta.	 Age >18 years. Must have an aneurysm/ulcer of the thoracic aorta.

For more information about clinical trials at Cooper, please contact:

Barbara C. • Cooper Research Institute • 401 Haddon Avenue, Room 140 • Camden, NJ 08103 • P: 856.536.1030 • F: 856.536.1039



We invite you to sign up for:

CooperCare Link

Stay connected to your patients' real-time Clinical Information

What is CooperCare Link? CooperCare Link is a web-based portal that provides real-time information about patients throughout their stay at Cooper.

Visit CooperCareLink.CooperHealth.org or call 856.361.1697 for registration and additional information. Email the Cooper Privacy Officer at PrivacyOfficer@CooperHealth.edu for technical support to reset passwords, add or delete users, or to troubleshoot issues.

Benefits Include:

- View your patients' records in real-time
- View Cooper test and lab results
- Order Cooper labs and medical imaging
- Schedule a patient appointment with a Cooper specialist
- Secure communication with your Cooper colleagues



SJMedicalReport.com